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Sir 
Fructosamine; is the current interest in alternative glycaemic markers justified? 
T e interest in alternative glycaemic markers, suc  as fructosamine,  as been rekindled due 
to increasing data on t eir ability to improve diagnosis [1] and predict onset and 
complications [2] of diabetes. Furt er clinical validation of t ese markers is called for [3] 
 owever t e limitations must also be elucidated so, rat er like HbA1c, t e non-glycaemic 
p ysiological, pat ological and analytical variables become well known. 
Many of t e variables t at affect HbA1c appear to similarly affect fructosamine despite t e 
different p ysiological compartments. T e most commonly known non-glycaemic factor 
affecting fructosamine is albumin [3] alt oug  data on t is is conflicting. We recently 
reported a multivariable univariate linear regression model of fructosamine (Table 3) [4] in 
w ic  t e effect of et nicity (Sout  Asian versus Caucasian), sex, age, presence of c ronic 
kidney disease (CKD), vitamin B12, ferritin, folate,  aemoglobin, mean cell volume (MCV), 
fasting glucose, HbA1c, albumin and C reactive protein (CRP) were examined [4]. T e 
significant affect of albumin levels was confirmed as were t e effects of et nicity, age, 
presence of CKD (primarily CKD stage 3 versus CKD <3), vitamin B12, folate, albumin, 
CRP, fasting glucose levels, HbA1c and  aemoglobin. Ferritin, MCV and sex were t e only 
non-significant variables [4]. 
T e large number of significant variables  ad not been anticipated, included due to t eir 
establis ed effect on HbA1c, confirming our current poor grasp of fructosamine metabolism. 
Body mass index is also negatively associated wit fructosamine in t ose wit out diabetes [5] 
and falls during pregnancy [6] furt er complicating its interpretation. T yroid status may 
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affect fructosamine interpretation [3]  owever not necessarily independently of deranged 
glucose and protein metabolism [7]. 
We, t erefore, read wit  interest t e new data but would urge caution on t e widespread 
adoption of fructosamine until t e significance of non-glycaemic variables can be establis ed 
in t e clinical field. In particular HbA1c remains t e biomarker of c oice for monitoring 
glycaemic control in t ose wit  CKD [8], w ereas fructosamine s ould be used wit caution 
[4]. 
Yours sincerely 
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